{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T20:03:02Z","timestamp":1784750582953,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Med"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s40290-025-00558-x","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T08:11:52Z","timestamp":1744359112000},"page":"199-207","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cost and Duration of Clinical Trials in Drug Development by Japanese Pharmaceutical Companies"],"prefix":"10.1007","volume":"39","author":[{"given":"Norihiro","family":"Okada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"key":"558_CR1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jhealeco.2016.01.012","volume":"47","author":"JA DiMasi","year":"2016","unstructured":"DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ. 2016;47:20\u201333. https:\/\/doi.org\/10.1016\/j.jhealeco.2016.01.012.","journal-title":"J Health Econ"},{"key":"558_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.760762","volume":"8","author":"S Simoens","year":"2021","unstructured":"Simoens S, Huys I. R&D costs of new medicines: a landscape analysis. Front Med (Lausanne). 2021;8: 760762. https:\/\/doi.org\/10.3389\/fmed.2021.760762.","journal-title":"Front Med (Lausanne)."},{"issue":"7","key":"558_CR3","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/d41573-019-00074-z","volume":"18","author":"H Dowden","year":"2019","unstructured":"Dowden H, Munro J. Trends in clinical success rates and therapeutic focus. Nat Rev Drug Discov. 2019;18(7):495\u20136. https:\/\/doi.org\/10.1038\/d41573-019-00074-z.","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"558_CR4","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1002\/cpt.2513","volume":"111","author":"RL Lalonde","year":"2022","unstructured":"Lalonde RL, Peck CC. Probability of success: a crucial concept to inform decision making in pharmaceutical research and development. Clin Pharmacol Ther. 2022;111(5):1001\u20133. https:\/\/doi.org\/10.1002\/cpt.2513.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"558_CR5","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrd3078","volume":"9","author":"SM Paul","year":"2010","unstructured":"Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: the pharmaceutical industry\u2019s grand challenge. Nat Rev Drug Discov. 2010;9(3):203\u201314. https:\/\/doi.org\/10.1038\/nrd3078.","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"558_CR6","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1001\/jama.2020.1166","volume":"323","author":"OJ Wouters","year":"2020","unstructured":"Wouters OJ, McKee M, Luyten J. Estimated research and development investment needed to bring a new medicine to market, 2009\u20132018. JAMA. 2020;323(9):844\u201353. https:\/\/doi.org\/10.1001\/jama.2020.1166.","journal-title":"JAMA"},{"issue":"2","key":"558_CR7","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1177\/1740774515625964","volume":"13","author":"A Sertkaya","year":"2016","unstructured":"Sertkaya A, Wong HH, Jessup A, Beleche T. Key cost drivers of pharmaceutical clinical trials in the United States. Clin Trials. 2016;13(2):117\u201326. https:\/\/doi.org\/10.1177\/1740774515625964.","journal-title":"Clin Trials"},{"issue":"6","key":"558_CR8","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nrd.2017.70","volume":"16","author":"L Martin","year":"2017","unstructured":"Martin L, Hutchens M, Hawkins C, Radnov A. How much do clinical trials cost? Nat Rev Drug Discov. 2017;16(6):381\u20132. https:\/\/doi.org\/10.1038\/nrd.2017.70.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"558_CR9","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/biostatistics\/kxx069","volume":"20","author":"CH Wong","year":"2019","unstructured":"Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. Biostatistics. 2019;20(2):273\u201386. https:\/\/doi.org\/10.1093\/biostatistics\/kxx069.","journal-title":"Biostatistics"},{"key":"558_CR10","doi-asserted-by":"publisher","unstructured":"Moore TJ, Heyward J, Anderson G, Alexander GC. Variation in the estimated costs of pivotal clinical benefit trials supporting the US approval of new therapeutic agents, 2015\u20132017: a cross-sectional study.\u00a0BMJ Open. 2020;10(6):e038863. Published 2020 Jun 11. https:\/\/doi.org\/10.1136\/bmjopen-2020-038863","DOI":"10.1136\/bmjopen-2020-038863"},{"key":"558_CR11","doi-asserted-by":"publisher","unstructured":"Jayasundara K, Hollis A, Krahn M, Mamdani M, Hoch JS, Grootendorst P. Estimating the clinical cost of drug development for orphan versus non-orphan drugs.\u00a0Orphanet J Rare Dis. 2019;14(1):12. Published 2019 Jan 10. https:\/\/doi.org\/10.1186\/s13023-018-0990-4","DOI":"10.1186\/s13023-018-0990-4"},{"issue":"11","key":"558_CR12","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1001\/jamainternmed.2018.3931","volume":"178","author":"TJ Moore","year":"2018","unstructured":"Moore TJ, Zhang H, Anderson G, Alexander GC. Estimated costs of pivotal trials for novel therapeutic agents approved by the US Food and Drug Administration, 2015\u20132016. JAMA Intern Med. 2018;178(11):1451\u20137. https:\/\/doi.org\/10.1001\/jamainternmed.2018.3931.","journal-title":"JAMA Intern Med"},{"issue":"4","key":"558_CR13","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1007\/s43441-024-00649-y","volume":"58","author":"M Hidaka","year":"2024","unstructured":"Hidaka M, Hanaoka H, Uyama Y. Different development strategies affecting japan\u2019s drug lag between Japan-based and foreign-based companies. Ther Innov Regul Sci. 2024;58(4):714\u201320. https:\/\/doi.org\/10.1007\/s43441-024-00649-y.","journal-title":"Ther Innov Regul Sci."},{"key":"558_CR14","unstructured":"Office of Pharmaceutical Industry Research. Research Paper No.82. 2024. https:\/\/www.jpma.or.jp\/opir\/research\/rs_082\/article_082.html. Accessed 25 Nov 2024 (in Japanese)."},{"issue":"3","key":"558_CR15","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1177\/1740774519839391","volume":"16","author":"Y Qiao","year":"2019","unstructured":"Qiao Y, Alexander GC, Moore TJ. Globalization of clinical trials: variation in estimated regional costs of pivotal trials, 2015\u20132016. Clin Trials. 2019;16(3):329\u201333. https:\/\/doi.org\/10.1177\/1740774519839391.","journal-title":"Clin Trials"},{"key":"558_CR16","unstructured":"Japan Pharmaceutical Manufacturers Association. Data book 2024. 2024. https:\/\/www.jpma.or.jp\/news_room\/issue\/databook\/en\/index.html. Accessed 25 Nov 2024."},{"issue":"5","key":"558_CR17","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1002\/cpt.2080","volume":"109","author":"M Tanaka","year":"2021","unstructured":"Tanaka M, Idei M, Sakaguchi H, et al. Evolving landscape of new drug approval in Japan and lags from international birth dates: retrospective regulatory analysis. Clin Pharmacol Ther. 2021;109(5):1265\u201373. https:\/\/doi.org\/10.1002\/cpt.2080.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"558_CR18","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1177\/2168479016648733","volume":"50","author":"HE Glass","year":"2016","unstructured":"Glass HE, Glass LM, Tran P, Alghamdi H. Pharmaceutical organizational size and phase 3 clinical trial completion times. Ther Innov Regul Sci. 2016;50(6):801\u20137. https:\/\/doi.org\/10.1177\/2168479016648733.","journal-title":"Ther Innov Regul Sci."},{"issue":"1","key":"558_CR19","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1177\/1740774507087551","volume":"5","author":"EL Eisenstein","year":"2008","unstructured":"Eisenstein EL, Collins R, Cracknell BS, et al. Sensible approaches for reducing clinical trial costs. Clin Trials. 2008;5(1):75\u201384. https:\/\/doi.org\/10.1177\/1740774507087551.","journal-title":"Clin Trials"},{"issue":"2","key":"558_CR20","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1177\/1740774518820060","volume":"16","author":"C Bentley","year":"2019","unstructured":"Bentley C, Cressman S, van der Hoek K, Arts K, Dancey J, Peacock S. Conducting clinical trials-costs, impacts, and the value of clinical trials networks: a scoping review. Clin Trials. 2019;16(2):183\u201393. https:\/\/doi.org\/10.1177\/1740774518820060.","journal-title":"Clin Trials"}],"container-title":["Pharmaceutical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-025-00558-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40290-025-00558-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-025-00558-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T09:00:37Z","timestamp":1748682037000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40290-025-00558-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["558"],"URL":"https:\/\/doi.org\/10.1007\/s40290-025-00558-x","relation":{},"ISSN":["1178-2595","1179-1993"],"issn-type":[{"value":"1178-2595","type":"print"},{"value":"1179-1993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]},"assertion":[{"value":"23 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors received no external financial support for the research, authorship or publication of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"N.O. is an employee of Chugai Pharmaceutical Co., Ltd. Y.T. is an employee of Nippon Shinyaku Co., Ltd.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The datasets analyzed during the current study are not publicly available as they contain information that could reveal nonpublic details from individual companies. However, they are available from the corresponding author on reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Analyses were performed using the statistical software R version 4.3.0. The code is available from the corresponding author on reasonable request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"N.O. designed the study, analyzed and interpreted data, and wrote the manuscript. Y.T. designed the study, collected and interpreted data, and wrote the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"The views expressed in this article are those of the authors and do not necessarily represent the official views of the Office of Pharmaceutical Industry Research.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Additional information"}}]}}